| Drug ID: | Drug32 |
|---|---|
| Drug Name: | Omeprazole |
| CID: | 4594 |
| DrugBank ID: | DB00338 |
| Modality: | Small Molecule |
| Groups: | approved|investigational |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT01287195, , NCT02760615, , NCT03358706 |
| Molecular Formula: | C17H19N3O3S |
| Molecular Weight: | 345.4 g/mol |
| Isomeric SMILES: | CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC |
| Synonyms: | omeprazole; 73590-58-6; Losec; Antra; Audazol; Omeprazon; Mopral; Omapren; Parizac; Ceprandal |
| Phase 0: | 10 |
| Phase 1: | 221 |
| Phase 2: | 40 |
| Phase 3: | 69 |
| Phase 4: | 104 |
| Description: | A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt296 | 4594 | Omeprazole | 495 | ATP4A | Homo sapiens (human) | Inhibitor | |
| dt297 | 4594 | Omeprazole | 495 | ATP4A | Homo sapiens (human) | None | |
| dt298 | 4594 | Omeprazole | 699 | BUB1 | Homo sapiens (human) | Activator | |
| dt299 | 4594 | Omeprazole | 5243 | ABCB1 | Homo sapiens (human) | None | |
| dt300 | 4594 | Omeprazole | 3074 | HEXB | Homo sapiens (human) | None | |
| dt301 | 4594 | Omeprazole | 7124 | TNF | Homo sapiens (human) | None | |
| dt302 | 4594 | Omeprazole | 1181 | CLCN2 | Homo sapiens (human) | None | |
| dt303 | 4594 | Omeprazole | 495 | ATP4A | Homo sapiens (human) | Inhibition | |
| dt304 | 4594 | Omeprazole | 496 | ATP4B | Homo sapiens (human) | 37713619 | Modulator |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT06917963 | Study of Treatment With Intensified Omeprazole Treatment to Prevent High Output Stoma 1 | NA | RECRUITING | Medical University of Gdansk | Stoma - Ileostomy|High Output Stoma|Colon Cancer|… | DRUG: Intensified intravenous omeprazole therapy … | Details |
| NCT03358706 | A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis | PHASE1 | TERMINATED | Janssen Research & Development, LLC | Crohn Disease|Ulcerative Colitis | DRUG: Ustekinumab IV Infusion|DRUG: Ustekinumab S… | Details |
| NCT02760615 | Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study | PHASE4 | WITHDRAWN | Takeda | Colitis, Ulcerative|Crohn Disease | DRUG: Caffeine|DRUG: Losartan|DRUG: Omeprazole|DR… | Details |
| NCT02272868 | Fecal Microbial Transplant in Pediatric Crohn's Disease | PHASE1|PHASE2 | TERMINATED | Seattle Children's Hospital | Crohn's Disease | BIOLOGICAL: Fecal Microbial transplant|DRUG: Norm… | Details |
| NCT06719622 | Evaluation of the Efficacy of Local Budesonide Treatment in Children with Crohn's Disease Located in the Esophagus And/or Stomach And/or Duodenum | PHASE2|PHASE3 | ENROLLING_BY_INVITATION | Medical University of Warsaw | Crohn Disease (CD) | DRUG: budesonide|DRUG: omeprazole (proton pump in… | Details |
| NCT01489943 | A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects | PHASE1 | COMPLETED | GlaxoSmithKline | Crohn's Disease | DRUG: GSK1605786 500 mg|DRUG: Midazolam 3 mg|DRUG… | Details |
| NCT01287195 | Oral OKT3 for the Treatment of Active Ulcerative Colitis | PHASE1|PHASE2 | COMPLETED | Brigham and Women's Hospital | Ulcerative Colitis | DRUG: Oral OKT3|DRUG: Omeprazole | Details |
| NCT00640809 | Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole | PHASE4 | COMPLETED | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Bowel Diseases, Inflammatory | DRUG: Celecoxib|OTHER: Placebo|DRUG: Ibuprofen pl… | Details |
| ACTRN12615000936527 | Relative Bioavailability and Effect of Food and Esomeprazole on the Pharmacokinetics of PRN1008 in Healthy Volunteers | PHASE1 | Not Recruiting | Clinical Network Services Pty Ltd | Rheumatoid Arthritis;Inflammatory Bowel Disease;S… | This will be a single center, four-period, open-l… | Details |
| NCT03269916 | Fertility and Ovarian Reserve Function in the Patient With Inflammatory Bowel Disease | NA | UNKNOWN | Sixth Affiliated Hospital, Sun Yat-sen University | Fertility Disorders|Ovarian Reserve Function|Preg… | OTHER: Anti Mueller hormone|OTHER: Estrogen|OTHER… | Details |
| NCT06800326 | Diagnostic Concordance of MR Enterography and Ultrasound for Treatment Response Assessment in Crohn's Disease (MANTRA) | NULL | RECRUITING | University College, London | Crohn Disease | DIAGNOSTIC_TEST: Ultrasound|DIAGNOSTIC_TEST: MRE … | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Inhibition of Tryptophan Hydroxylases and Monoamine Oxidase-A by the Proton Pum…
PMID: 33324221
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Serotonin (5-HT) is a hormone and neurotransmitter that modulates neural activity as well as a wide range of other physiological processes including …
Pharmacokinetics of omeprazole in rats with dextran sulfate sodium-induced ulce…
PMID: 32354532
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Omeprazole is a commonly used drug in patients with ulcerative colitis (UC). This study investigated the pharmacokinetics of omeprazole in rats with …